$107,314.36 ownership Payment -- Boehringer Ingelheim to Dr. Steven Green
Boehringer Ingelheim reports $107,314 ownership interest to Internal Medicine physician for Rybelsus
This page provides a detailed analysis of a $107,314.36 ownership payment from Boehringer Ingelheim to Dr. Steven Green. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $107,314.36 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Boehringer Ingelheim |
| Physician | Dr. Steven Green |
| NPI Number | 1913962123 |
| Physician Specialty | Internal Medicine |
| Location | City, VA |
| Date of Payment | 2025-01-13 |
| Related Drug/Device | Rybelsus |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Boehringer Ingelheim made a $107.3K ownership payment to Steven Green, a Internal Medicine specialist in City, VA. The payment was associated with Rybelsus. Boehringer Ingelheim reported an ownership interest valued at $107,314.36 to Dr. Steven Green, an Internal Medicine physician. This ownership interest is associated with Rybelsus, a drug manufactured by Boehringer Ingelheim. The payment was made on January 13, 2025, and is categorized as an 'Ownership or Investment Interest'.
Patient Guidance: What This Payment Means for You
This record indicates a physician has an ownership stake in the company that manufactures a drug. It's important to understand if this ownership influenced prescribing decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests can be common in the pharmaceutical industry, but the value of this specific interest relative to other Internal Medicine physicians' ownership stakes is not immediately clear without further data.
Regulatory Context: Sunshine Act Requirements
This disclosure is made under the Physician Payments Sunshine Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- boehringer-ingelheim
- rybelsus
- internal-medicine
- physician-payment
- cms-open-payments
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $107.3K payment for?
This was a ownership payment of $107.3K from Boehringer Ingelheim to Steven Green, categorized as "Ownership or Investment Interest". It was associated with Rybelsus. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Steven Green accept pharmaceutical money?
Yes, Steven Green received this $107.3K payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Steven Green's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $107.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Internal Medicine?
To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Steven Green's relationship with Boehringer Ingelheim?
The payment represents an ownership or investment interest, not a direct payment for services. This $107.3K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Internal Medicine?
The specific nature of the ownership interest (e.g., stock, partnership) is not detailed in this record.
What should patients do after learning about this payment?
This record indicates a physician has an ownership stake in the company that manufactures a drug. It's important to understand if this ownership influenced prescribing decisions.
What else should I know about this ownership payment?
Dr. Green's specialty is Internal Medicine, and the associated drug is Rybelsus.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.